Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
The positive data from Apellis' Phase 3 study on pegcetacoplan was published in The Lancet, targeting the main cause of blindness in the elderly
1 November 2023
Recently, Apellis Pharmaceuticals announced that The Lancet published positive 24-month results from the Phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan) .
Drug Insights
3 min read
Exploring Dactinomycin's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
1 November 2023
This article summarized the latest R&D progress of Dactinomycin, the Mechanism of Action for Dactinomycin, and the drug target R&D trends for Dactinomycin.
Latest Hotspot
4 min read
The latest phase II clinical research by Innovent Biologics on Mazdutide, a GLP-1R/GCGR dual agonist, has been released, showing significant weight loss effects
1 November 2023
Innovent Biologics recently announced the completion of the 48-week treatment phase after reaching the primary endpoint of the phase II clinical trial in obese Chinese subjects with 9mg of the GLP-1R/GCGR dual agonist, Mazdutide.
Advanced Tech.
6 min read
Molecular Glue: It bonds proteins and challenges the undruggable
1 November 2023
Molecular glue can enhance and stabilize protein interactions; it can also repair protein interactions that have been weakened due to mutations.
Latest Hotspot
3 min read
The Eli Lilly IL-13 inhibitor, lebrikizumab, demonstrates long-term efficacy for the treatment of moderate-to-severe atopic dermatitis
1 November 2023
Recently, Eli Lilly announced the long-term therapeutic effects of its investigational IL-13 inhibitor, lebrikizumab, in patients with moderate to severe atopic dermatitis.
Drug Insights
4 min read
Deep Scientific Insights on Dopamine hydrochloride's R&D Progress, Mechanism of Action, and Drug Target
1 November 2023
This article summarized the latest R&D progress of Dopamine hydrochloride, the mechanism of action for Dopamine hydrochloride, and the drug target R&D trends for Dopamine hydrochloride.
Latest Hotspot
3 min read
Abbisko Therapeutics' EGFR exon20ins inhibitor, ABSK112, has been approved for clinical use in China for the treatment of non-small cell lung cancer
1 November 2023
Recently, Abbisko Therapeutics announced that its independently developed next-generation EGFR Exon20ins inhibitor ABSK112 has received approval from the NMPA of China for clinical trial applications.
Valuable Targets
6 min read
Analysis on the Research Progress of COX Inhibitor
1 November 2023
Medicines that inhibit COX can alleviate inflammation and pain symptoms. Medications that inhibit Cyclooxygenase activity, such as aspirin, have been available to the public for around 100 years.
Latest Hotspot
3 min read
KangaBio's IL-12 prodrug molecule immunotherapy, KGX101, has been approved for clinical use in the United States for the treatment of advanced solid tumors
1 November 2023
Recently, KangaBio announced that its independently developed "Tumor-Specific Recombinant IL-12 Fc Fusion Protein for Injection" (pipeline code: KGX101) clinical trial application (IND) has been officially approved by the U.S. FDA.
Drug Insights
4 min read
Decoding Diroximel fumarate: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
1 November 2023
This article summarized the latest R&D progress of Diroximel fumarate, the Mechanism of Action for Diroximel fumarate, and the drug target R&D trends for Diroximel fumarate.
Latest Hotspot
3 min read
Phase 3 clinical results of Johnson & Johnson's IL-23 inhibitor Guselkumab are positive, significantly relieving symptoms in patients with ulcerative colitis
1 November 2023
Recently, Johnson & Johnson announced the results of its Phase 3 clinical trial for its anti-IL-23 antibody Tremfya (guselkumab) in treating moderate to severe ulcerative colitis (UC).
Valuable Targets
4 min read
Analysis on the Clinical Research Progress of PD-1 Agonist
1 November 2023
PD-1, or programmed cell death protein 1, is a crucial immune checkpoint receptor found on the surface of certain immune cells in the human body.